Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AWP class action proceeds

Executive Summary

AWP proposed class action will proceed against all defendants except Roche under a Boston federal judge's ruling. Judge Patti Saris declined to dismiss plaintiffs' claims that drug manufacturers and pharmacy benefit managers - who are not defendants in the case - engaged in racketeering with the objective of promoting fraudulent AWPs, and that manufacturers in the Together Rx discount drug card program engaged in a price-fixing conspiracy. The Together Rx allegations were included in an amended class action complaint in July (1"The Pink Sheet" Aug. 18, 2003, p. 11)...

You may also be interested in...

Together Rx Cited In AWP Price-Fixing Suit; Amended Complaint Drops Merck

A class action suit alleges manufacturers participating in the Together Rx discount drug card program are involved in a conspiracy to increase the average wholesale price "spread" on products in the program

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts